'On consolidated basis
Quarter ended March 2025 compared with Quarter ended March 2024.
Net sales (including other operating income) of Glaxosmithkline Pharmaceuticals has increased 4.79% to Rs 974.37 crore. Operating profit margin has jumped from 27.67% to 34.20%, leading to 29.51% rise in operating profit to Rs 333.19 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 20.00% to 11.20%. Purchase of finished goods cost rose from 25.00% to 28.32%. Employee cost decreased from 16.89% to 14.87%. Other expenses rose from 12.96% to 13.24%.
Other income rose 36.37% to Rs 40.68 crore. PBIDT rose 30.23% to Rs 373.87 crore. Provision for interest fell 24.68% to Rs 0.58 crore. Loan funds declined from Rs 18.67 crore as of 31 March 2024 to Rs 9.95 crore as of 31 March 2025. Inventories declined from Rs 525.05 cror...
Pleaselogin & subscribe to view the full report.
More Reports
|
|